SEC Comment Letter for Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — Jun 22, 2017

Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: June 22, 2017 · CIK: 0000876343 · Accession: 0000000000-17-021930

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 22, 2017

Author

Michael West

Form

UPLOAD

Company

Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)

Letter

June 22, 2017 Michael West Co-Chief Executive Officer BioTime, Inc. 1010 Atlantic Avenue, Suite 102 Alameda, CA 94501 BioTime, Inc. Registration Statement on Form S-3 Filed June 16, 2017 File No. 333-218807Re: Dear Dr. West: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

June 22, 2017
Michael West
Co-Chief Executive Officer
BioTime, Inc.
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501
BioTime, Inc.
Registration Statement on Form S-3
Filed June 16, 2017
File No. 333-218807Re:
Dear Dr. West:
        This is to advise you that we have not reviewed and will not review your registration
statement.
        Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
        Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io